BIO / USDT

BIO / USDC

BIO / TRY

ALLO / TRY

ALLO / USDC

ALLO / USDT

NOM / USDC

NOM / TRY

NOM / USDT

KITE / USDT

ORCA / USDC

ORCA / USDT

ORCA / TRY

D / USDT

D / TRY

AWE / USDT

ESP / USDT

ESP / TRY

ESP / USDC

OP / BTC

KOTAKMAMC - NIFTY100EW

VL E GOV AND IT SOL LTD

KAYTEX FABRICS LIMITED

ITALIAN EDIBLES LIMITED

MARVEL DECOR LIMITED

BLB LIMITED

FROG INNOVATIONS LIMITED

DEE DEVELOPMENT ENG LTD

TREE HOUSE EDU LTD

SAKAR HEALTHCARE LIMITED

TAC INFOSEC LIMITED

NEWGEN SOFTWARE TECH LTD

D K ENTERPRISES GLOBAL L

VIKRAM SOLAR LIMITED

TRANSWORLD SHIP LINES LTD

POWER INSTRUMENT (G) LTD

C K K RETAIL MART LIMITED

SHIV AUM STEELS LIMITED

KN AGRI RESOURCES LIMITED

NEOCHEM BIO SOLUTIONS LTD

Click here to get full coverage on Indoco Remedies (NSE:INDOCO investor three-year losses grow to 42% as the stock sheds ₹2.2b this past week - simplywall.st

Indoco Remedies (NSE:INDOCO investor three-year losses grow to 42% as the stock sheds ₹2.2b this past week  simplywall.st

Indoco Remedies (NSE:INDOCO investor three-year losses grow to 42% as the stock sheds ₹2.2b this past week - simplywall.st

Click here to get full coverage on Indoco Remedies Releases Q3 FY26 Earnings Call Transcript - TipRanks

Indoco Remedies Releases Q3 FY26 Earnings Call Transcript  TipRanks

Indoco Remedies Releases Q3 FY26 Earnings Call Transcript - TipRanks

Click here to get full coverage on Indoco Remedies Ltd is Rated Strong Sell - Markets Mojo

Indoco Remedies Ltd is Rated Strong Sell  Markets Mojo

Indoco Remedies Ltd is Rated Strong Sell - Markets Mojo

Click here to get full coverage on Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva - Yahoo Finance

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva  Yahoo Finance

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva - Yahoo Finance

Click here to get full coverage on Indoco Remedies Receives USFDA Approval for Lacosamide Oral Solution ANDA - Medical Dialogues

Indoco Remedies Receives USFDA Approval for Lacosamide Oral Solution ANDA  Medical Dialogues

Indoco Remedies Receives USFDA Approval for Lacosamide Oral Solution ANDA - Medical Dialogues

Click here to get full coverage on Indoco Remedies gets USFDA nod to sell generic epilepsy medicine - The Economic Times

Indoco Remedies gets USFDA nod to sell generic epilepsy medicine  The Economic Times

Indoco Remedies gets USFDA nod to sell generic epilepsy medicine - The Economic Times

Click here to get full coverage on Indoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solution - CNBC TV18

Indoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solution  CNBC TV18

Indoco Remedies shares gain over 8.5% post USFDA approval for Lacosamide oral solution - CNBC TV18

Click here to get full coverage on Indoco Remedies receives USFDA approval for Lacosamide Oral Solution - Business Standard

Indoco Remedies receives USFDA approval for Lacosamide Oral Solution  Business Standard

Indoco Remedies receives USFDA approval for Lacosamide Oral Solution - Business Standard

Click here to get full coverage on Indoco Remedies Posts Quarterly Loss Amid One-Time Labour Code Impact and Higher Costs - TipRanks

Indoco Remedies Posts Quarterly Loss Amid One-Time Labour Code Impact and Higher Costs  TipRanks

Indoco Remedies Posts Quarterly Loss Amid One-Time Labour Code Impact and Higher Costs - TipRanks

Click here to get full coverage on Indoco Remedies Shares Soar 7% on Securing USFDA Final Approval - Equitypandit

Indoco Remedies Shares Soar 7% on Securing USFDA Final Approval  Equitypandit

Indoco Remedies Shares Soar 7% on Securing USFDA Final Approval - Equitypandit

Click here to get full coverage on Indoco Remedies Allots 55,700 Equity Shares Under Employee Stock Option Plan-2022 - scanx.trade

Indoco Remedies Allots 55,700 Equity Shares Under Employee Stock Option Plan-2022  scanx.trade

Indoco Remedies Allots 55,700 Equity Shares Under Employee Stock Option Plan-2022 - scanx.trade

Click here to get full coverage on Indoco Remedies Consolidated December 2025 Net Sales at Rs 445.36 crore, up 8.48% Y-o-Y - Moneycontrol

Indoco Remedies Consolidated December 2025 Net Sales at Rs 445.36 crore, up 8.48% Y-o-Y  Moneycontrol

Indoco Remedies Consolidated December 2025 Net Sales at Rs 445.36 crore, up 8.48% Y-o-Y - Moneycontrol

Click here to get full coverage on Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely - simplywall.st

Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely  simplywall.st

Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely - simplywall.st

Click here to get full coverage on Indoco Remedies says Maharashtra GST inspection completed, operations unaffected - CNBC TV18

Indoco Remedies says Maharashtra GST inspection completed, operations unaffected  CNBC TV18

Indoco Remedies says Maharashtra GST inspection completed, operations unaffected - CNBC TV18

Click here to get full coverage on Indoco Remedies Ltd Faces Bearish Momentum Amid Technical Downturn - Markets Mojo

Indoco Remedies Ltd Faces Bearish Momentum Amid Technical Downturn  Markets Mojo

Indoco Remedies Ltd Faces Bearish Momentum Amid Technical Downturn - Markets Mojo

Click here to get full coverage on Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban - Medical Dialogues

Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban  Medical Dialogues

Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban - Medical Dialogues

Click here to get full coverage on Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution Generic - scanx.trade

Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution Generic  scanx.trade

Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution Generic - scanx.trade

Click here to get full coverage on Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259 - simplywall.st

Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259  simplywall.st

Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259 - simplywall.st

Click here to get full coverage on Indoco Remedies shares gain after Q2 net loss improves, revenue rises 12% - CNBC TV18

Indoco Remedies shares gain after Q2 net loss improves, revenue rises 12%  CNBC TV18

Indoco Remedies shares gain after Q2 net loss improves, revenue rises 12% - CNBC TV18

Click here to get full coverage on Indoco Remedies Shows Strong Rebound Amid Broader Small-Cap Market Gains - Markets Mojo

Indoco Remedies Shows Strong Rebound Amid Broader Small-Cap Market Gains  Markets Mojo

Indoco Remedies Shows Strong Rebound Amid Broader Small-Cap Market Gains - Markets Mojo

Click here to get full coverage on Indoco Remedies: Kare Family Trust Completes Substantial Share Acquisition - scanx.trade

Indoco Remedies: Kare Family Trust Completes Substantial Share Acquisition  scanx.trade

Indoco Remedies: Kare Family Trust Completes Substantial Share Acquisition - scanx.trade

Click here to get full coverage on Indoco Remedies Standalone December 2025 Net Sales at Rs 400.51 crore, up 7.38% Y-o-Y - Moneycontrol

Indoco Remedies Standalone December 2025 Net Sales at Rs 400.51 crore, up 7.38% Y-o-Y  Moneycontrol

Indoco Remedies Standalone December 2025 Net Sales at Rs 400.51 crore, up 7.38% Y-o-Y - Moneycontrol

Click here to get full coverage on Indoco Remedies' EBITDA Surges 163% Amidst International Growth - Whalesbook

Indoco Remedies' EBITDA Surges 163% Amidst International Growth  Whalesbook

Indoco Remedies' EBITDA Surges 163% Amidst International Growth - Whalesbook

Click here to get full coverage on Indoco Remedies Q2FY26 Revenue Up, Net Loss at ₹921 Lakh - HDFC Sky

Indoco Remedies Q2FY26 Revenue Up, Net Loss at ₹921 Lakh  HDFC Sky

Indoco Remedies Q2FY26 Revenue Up, Net Loss at ₹921 Lakh - HDFC Sky

Click here to get full coverage on Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood - Medical Dialogues

Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood  Medical Dialogues

Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood - Medical Dialogues

Click here to get full coverage on Indoco Remedies gains final ANDA approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg - Express Pharma

Indoco Remedies gains final ANDA approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg  Express Pharma

Indoco Remedies gains final ANDA approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg - Express Pharma

Click here to get full coverage on Indoco Remedies reports consolidated net loss of Rs 29.79 crore in the December 2025 quarter - Business Standard

Indoco Remedies reports consolidated net loss of Rs 29.79 crore in the December 2025 quarter  Business Standard

Indoco Remedies reports consolidated net loss of Rs 29.79 crore in the December 2025 quarter - Business Standard

Click here to get full coverage on Indoco Remedies Ltd Hits Intraday High with 9.22% Surge on 3 Feb 2026 - Markets Mojo

Indoco Remedies Ltd Hits Intraday High with 9.22% Surge on 3 Feb 2026  Markets Mojo

Indoco Remedies Ltd Hits Intraday High with 9.22% Surge on 3 Feb 2026 - Markets Mojo

Click here to get full coverage on Indoco Remedies Q3 Results: Net loss widens, margin expands from last year - CNBC TV18

Indoco Remedies Q3 Results: Net loss widens, margin expands from last year  CNBC TV18

Indoco Remedies Q3 Results: Net loss widens, margin expands from last year - CNBC TV18

Click here to get full coverage on Indoco Remedies Faces Mixed Technical Trends Amid Market Volatility and Underperformance - Markets Mojo

Indoco Remedies Faces Mixed Technical Trends Amid Market Volatility and Underperformance  Markets Mojo

Indoco Remedies Faces Mixed Technical Trends Amid Market Volatility and Underperformance - Markets Mojo

Click here to get full coverage on USFDA successfully completes inspection at Indoco Remedies Mumbai API facility - Medical Dialogues

USFDA successfully completes inspection at Indoco Remedies Mumbai API facility  Medical Dialogues

USFDA successfully completes inspection at Indoco Remedies Mumbai API facility - Medical Dialogues

Click here to get full coverage on What drove Indoco Remedies share price 6% higher today? Top details inside - Business Standard

What drove Indoco Remedies share price 6% higher today? Top details inside  Business Standard

What drove Indoco Remedies share price 6% higher today? Top details inside - Business Standard

Click here to get full coverage on Indoco Remedies shares rise 5% on receiving EIR for Patalganga API unit - Business Standard

Indoco Remedies shares rise 5% on receiving EIR for Patalganga API unit  Business Standard

Indoco Remedies shares rise 5% on receiving EIR for Patalganga API unit - Business Standard

Click here to get full coverage on Indoco Remedies Secures USFDA Nod for Epilepsy Drug - Whalesbook

Indoco Remedies Secures USFDA Nod for Epilepsy Drug  Whalesbook

Indoco Remedies Secures USFDA Nod for Epilepsy Drug - Whalesbook

Click here to get full coverage on Indoco Remedies Faces Challenging Market Assessment Amidst Financial and Technical Shifts - Markets Mojo

Indoco Remedies Faces Challenging Market Assessment Amidst Financial and Technical Shifts  Markets Mojo

Indoco Remedies Faces Challenging Market Assessment Amidst Financial and Technical Shifts - Markets Mojo

Click here to get full coverage on Indoco Remedies Receives USFDA EIR for API Manufacturing Facility at Patalganga - scanx.trade

Indoco Remedies Receives USFDA EIR for API Manufacturing Facility at Patalganga  scanx.trade

Indoco Remedies Receives USFDA EIR for API Manufacturing Facility at Patalganga - scanx.trade

Click here to get full coverage on Indoco Remedies Ltd Sees Mixed Technical Signals Amid Price Momentum Shift - Markets Mojo

Indoco Remedies Ltd Sees Mixed Technical Signals Amid Price Momentum Shift  Markets Mojo

Indoco Remedies Ltd Sees Mixed Technical Signals Amid Price Momentum Shift - Markets Mojo

Click here to get full coverage on Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show - Business Standard

Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show  Business Standard

Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show - Business Standard

Click here to get full coverage on Indoco Remedies subsidiary launches generic drug in UK - ET Pharma

Indoco Remedies subsidiary launches generic drug in UK  ET Pharma

Indoco Remedies subsidiary launches generic drug in UK - ET Pharma

Click here to get full coverage on Indoco Remedies Reports 9% Revenue Growth in Q2, Despite Challenges - scanx.trade

Indoco Remedies Reports 9% Revenue Growth in Q2, Despite Challenges  scanx.trade

Indoco Remedies Reports 9% Revenue Growth in Q2, Despite Challenges - scanx.trade

Click here to get full coverage on Indoco Remedies shares rise as it receives EU 'Good Manufacturing Practices' certificate - CNBC TV18

Indoco Remedies shares rise as it receives EU 'Good Manufacturing Practices' certificate  CNBC TV18

Indoco Remedies shares rise as it receives EU 'Good Manufacturing Practices' certificate - CNBC TV18

Click here to get full coverage on Indoco Remedies Faces Evaluation Shift Amid Ongoing Financial Challenges and Mixed Performance - Markets Mojo

Indoco Remedies Faces Evaluation Shift Amid Ongoing Financial Challenges and Mixed Performance  Markets Mojo

Indoco Remedies Faces Evaluation Shift Amid Ongoing Financial Challenges and Mixed Performance - Markets Mojo

Click here to get full coverage on Indoco Remedies Enters ₹24.65 Crore Sale-Leaseback Deal for Waluj Facility and CRO - scanx.trade

Indoco Remedies Enters ₹24.65 Crore Sale-Leaseback Deal for Waluj Facility and CRO  scanx.trade

Indoco Remedies Enters ₹24.65 Crore Sale-Leaseback Deal for Waluj Facility and CRO - scanx.trade

Click here to get full coverage on Indoco Remedies Faces Mixed Technical Trends Amid Ongoing Market Challenges - Markets Mojo

Indoco Remedies Faces Mixed Technical Trends Amid Ongoing Market Challenges  Markets Mojo

Indoco Remedies Faces Mixed Technical Trends Amid Ongoing Market Challenges - Markets Mojo

Click here to get full coverage on Indoco Remedies gets Certificate of EU GMP Compliance for Goa sterile drug product manufacturing facility - Medical Dialogues

Indoco Remedies gets Certificate of EU GMP Compliance for Goa sterile drug product manufacturing facility  Medical Dialogues

Indoco Remedies gets Certificate of EU GMP Compliance for Goa sterile drug product manufacturing facility - Medical Dialogues

Click here to get full coverage on Indoco Remedies Q3 FY26: Mounting Losses Deepen as Operational Challenges Persist - Markets Mojo

Indoco Remedies Q3 FY26: Mounting Losses Deepen as Operational Challenges Persist  Markets Mojo

Indoco Remedies Q3 FY26: Mounting Losses Deepen as Operational Challenges Persist - Markets Mojo

Click here to get full coverage on Indoco Remedies Technical Momentum Shifts Amid Market Challenges - Markets Mojo

Indoco Remedies Technical Momentum Shifts Amid Market Challenges  Markets Mojo

Indoco Remedies Technical Momentum Shifts Amid Market Challenges - Markets Mojo

Click here to get full coverage on Indoco Remedies Technical Momentum Shifts Amid Bearish Market Signals - Markets Mojo

Indoco Remedies Technical Momentum Shifts Amid Bearish Market Signals  Markets Mojo

Indoco Remedies Technical Momentum Shifts Amid Bearish Market Signals - Markets Mojo

Click here to get full coverage on Indoco Remedies Ltd Faces Intensified Bearish Momentum Amid Technical Downgrade - Markets Mojo

Indoco Remedies Ltd Faces Intensified Bearish Momentum Amid Technical Downgrade  Markets Mojo

Indoco Remedies Ltd Faces Intensified Bearish Momentum Amid Technical Downgrade - Markets Mojo

Click here to get full coverage on Indoco Remedies Awarded EU GMP Certification for Sterile Drug Manufacturing at Goa Plant II - Machine Maker

Indoco Remedies Awarded EU GMP Certification for Sterile Drug Manufacturing at Goa Plant II  Machine Maker

Indoco Remedies Awarded EU GMP Certification for Sterile Drug Manufacturing at Goa Plant II - Machine Maker

Click here to get full coverage on Indoco Remedies gets USFDA EIR for Patalganga facility - Medical Dialogues

Indoco Remedies gets USFDA EIR for Patalganga facility  Medical Dialogues

Indoco Remedies gets USFDA EIR for Patalganga facility - Medical Dialogues

Click here to get full coverage on Indoco Remedies Ltd Opens with Strong Gap Up Reflecting Positive Market Momentum - Markets Mojo

Indoco Remedies Ltd Opens with Strong Gap Up Reflecting Positive Market Momentum  Markets Mojo

Indoco Remedies Ltd Opens with Strong Gap Up Reflecting Positive Market Momentum - Markets Mojo

Click here to get full coverage on Indoco Remedies reports net loss of ₹35.6 crore in Q1, margin contracts - CNBC TV18

Indoco Remedies reports net loss of ₹35.6 crore in Q1, margin contracts  CNBC TV18

Indoco Remedies reports net loss of ₹35.6 crore in Q1, margin contracts - CNBC TV18

Click here to get full coverage on Indoco Remedies Posts Revenue Growth Amidst Widening Losses, Going Concern Doubts Emerge - Whalesbook

Indoco Remedies Posts Revenue Growth Amidst Widening Losses, Going Concern Doubts Emerge  Whalesbook

INDOCO

Price Chart

Key Statistics

Technicals

About INDOCO

Latest News

Indoco Remedies (NSE:INDOCO investor three-year losses grow to 42% as the stock sheds ₹2.2b this past week - simplywall.st

Indoco Remedies Releases Q3 FY26 Earnings Call Transcript - TipRanks

Indoco Remedies Ltd is Rated Strong Sell - Markets Mojo

Advanced Charts

Top Gainers

Top Losers